Aesha Patel, DO

UAB Internal Medicine Chief Resident | Current PGY-2 | Aspiring Cardiologist (opinions my own)

[Borge G Nordestgaard @BNordestgaard]

JACC STATE-OF-THE-ART REVIEW: do you have problems understanding all the new drugs to lower triglycerides and remnant cholesterol: lipid and side effects, target populations, approved or not by FDA+EMA? Ask Tybjærg Nordestgaard et al explain the details
https://t.co/IwwED8JYfE

[American College of Cardiology @ACCinTouch]

🆕 #ACCEd Tackles hs-CRP’s Role in #CVD

Check out the infographic 👇 which details the role of hs-CRP and influencing factors, along with materials on hs-CRP codes, recommendations, approaches, and further research.

Explore the course: https://t.co/Nqck7RGSEl

[AJPC @AJPCardio]

New @ASPCardio Clinical Practice Statement🫀: Framework to improve cardiometabolic care for South Asians—individual to population level. https://t.co/eKZbl4xUXP
@pnatarajanmd @jaideeppatelmd @dranandrohatgi @DrMarthaGulati @CiccaroneCenter
#SouthAsianHealth #HeartHealth #ASPC

[American College of Cardiology @ACCinTouch]

C-reactive protein (CRP) is a marker of inflammation and can help predict #heartdisease risk

📄 Help your patients understand CRP, inflammation and how it affects the heart with #CardioSmart’s latest infographic. Learn more: https://t.co/nZ8XEc9R5T

[AHA Science @AHAScience]

Palliative care in advanced CVD is essential to enhance quality of life, extending beyond end-of-life care to encompass the entire disease course.

✍🏼 @GravenLucinda @DeanLisaKitko @AbshireMartha @kofi_larry @Angie_Durante89 @LorraineEvang12 @FiedlerAmy @AL_CardiacRN

[Ritika Tuli @RitikaTuliMD]

#CardioNuggets

The Reynolds Risk Score refines 10-year CV risk—especially in women:

✅ Uses: Age, SBP, TC, HDL, hs-CRP, smoking, family hx
🔍 More accurate than Framingham for women

Ideal for primary prevention decisions.

#CardioTwitter #Prevention #Lipids

[AHA Science @AHAScience]

CVD is the most common cause of death for people with kidney failure.

CKM syndrome is defined as a health disorder caused by the connections among obesity, diabetes, chronic kidney disease & CVD.

📷 Algorithm for managing patients with CKM syndrome Stage 4

[American College of Cardiology @ACCinTouch]

ACC’s #CardioSmart recently launched a 🆕 app, CardioSmart360, designed to support treatment discussions between patients and their health care team.

Find out more and download the new CardioSmart360 app for free! ➡️ https://t.co/6FhuZOFW61 #CardioX

[EHJ Editor-in-Chief @ehj_ed]

Time to rethink how we monitor and manage silent atrial fibrillation. New meta-analysis sheds light on symptomatic vs. asymptomatic atrial fibrillation. Raed more in#EHJ.
https://t.co/ESoN7t2bxg
#cardiotwitter @ESC_Journals @escardio

[Dr. Hinal Rathi, DO @HinalRathi]

So grateful and honored to be co-chief resident with @aeshp_17! Learning so much at the Alliance for Academic Internal Medicine Conference!

#chiefresidents #MedicalInnovation @uabmedicine #womeninSTEM #internalmedicine

[Sek Kathiresan MD @skathire]

For Lp(a), key therapeutic question remains: will lowering of Lp(a) reduce risk for cardiovascular events?

Four subquestions:
1. how much Lp(a) lowering do you need [magnitude of Lp(a) lowering]
2. for how long [duration of treatment required]
3. in which patients [threshold of baseline Lp(a) level]
4. will lead to how much MACE reduction [magnitude of risk reduction] ?

These questions should be answered collectively after the execution of three CVOT over next few years:
1. pelacarsen (HORIZON trial)
2. olpasiran (OCEAN trial)
3. lepodisiran (ACCLAIM trial)

[Soumyadeep Bag @sbag_in]

It was a privilege to present 3 posters at #ACC25. Thank you Chicago for having me and @ACCinTouch for the opportunity. Shout-out to my co- researches @aeshp_17 @CMotley1 @iAlinasehar. And thank you to my mentors @DrDudenbostel and Dr. Urvish Patel for your continued guidance.

[Aesha Patel, DO @aeshp_17]

Extremely grateful for the opportunity to present and experience #ACC25 representing UAB Huntsville with the best! Thank you for your encouragement and support @DrDudenbostel @CMotley1 @sbag_in @pruthap287

[American College of Cardiology @ACCinTouch]

DYK that 1 in 5 adults have an Lp(a) level that is too high. Use #CardioSmart’s Lp(a) Infographic to help patients understand this condition and how it might affect their heart. https://t.co/JYCt2FsnZP #Cholesterol #ACC25

[American College of Cardiology @ACCinTouch]

Limiting fluid intake may have no benefit for patients with #HeartFailure, according to findings from the FRESH-UP study presented during a Late-Breaking Clinical Trial session at #ACC25.

Check out the key findings ➡️ https://t.co/hVqEY34Uie

[Soumyadeep Bag @sbag_in]

Loved representing @uabmedicine Huntsville @ACCinTouch . Thank you @DrDudenbostel for the support.
#ACC25 #Cardiology

[American College of Cardiology @ACCinTouch]

Educate your patients about CRP, inflammation and how it affects the heart with #CardioSmart’s latest infographic: https://t.co/QURRzRz8Dj #ACC25

[Davide Capodanno @DFCapodanno]

First day at #ACC25, here are the results of 10 trials presented today. I counted 3 NEJM, 1 Lancet, and 1 JAMA.

WARRIOR: Intensive medical therapy did not reduce major CV events at five years in women with suspected INOCA.
STRIDE: Semaglutide improved walking distance, symptoms, and quality of life in PAD with diabetes.
API-CAT: Low-dose apixaban was noninferior to full-dose for preventing VTE recurrence in cancer patients.
RIVAWAR: Rivaroxaban was as effective and safe as warfarin for post-MI LV thrombus resolution at three months.
FARES-II: Four-factor PCC was superior to frozen plasma for bleeding control in cardiac surgery.
REVERSE-IT: Bentracimab reversed ticagrelor’s antiplatelet effects in urgent surgery or major bleeding.
HOST-BR: Three-month DAPT reduced adverse events without more bleeding vs. one-month in high-bleeding-risk patients post-stent.
SOUL: Oral semaglutide reduced MACE by 14% over four years with no safety concerns.
ADVANCE-HTN: Lorundrostat significantly lowered systolic BP at 12 weeks in uncontrolled hypertension.
DAPA-TAVI: Dapagliflozin reduced mortality and heart failure worsening post-TAVI vs. standard care.

[AHA Science @AHAScience]

SOUL Results presented at #ACC25

[American College of Cardiology @ACCinTouch]

Poor dietary habits are a major risk factor for #CVD. Plant-based, Mediterranean & DASH diets have all demonstrated clear cardioprotective benefits in primary & secondary prevention.

More on heart-healthy eating ➡️ https://t.co/PtfZoJwMXs

#NationalNutritionMonth #CardioSmart